Navigation Links
Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial
Date:10/27/2011

ROCKVILLE, Md., Oct  27, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that it has completed Phase Ia in the ongoing safety trial to test its neuroregenerative small molecule drug, NSI-189, in the treatment of major depressive disorder (MDD).  Phase Ia tested the drug in healthy volunteers for safety and tolerability. Phase Ib, which the company expects to commence later this year, will test the safety and tolerability of NSI-189 in depressed patients.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in MDD and other diseases and conditions, such as Alzheimer's disease and post-traumatic stress disorder (PTSD).

"We are extremely pleased the trial has progressed so smoothly," said Karl Johe, PhD, Chief Scientific Officer and Chairman of Neuralstem's Board of Directors. "We didn't see any drug-related adverse effects in this set of patients. We are eager to move to the next phase of this safety trial, where we will be testing NSI-189 in patients who suffer from major depressive disorder."

About the Trial

This Phase Ia trial tested single ascending doses of NSI-189 in healthy patients. Standard safety endpoints were monitored.  All doses were well tolerated and there were no drug-related serious adverse events.  The trial will commence to the Ib phase, testing the safety of escalating doses of daily administration for 28 days in depressed patients. The entire Phase I trial is expected to be approximately one year in duration.

About NSI-189

NSI-189 is the lead compound in Neuralstem's neurogenerative small molecule drug platform
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neuralstem Announces Issuance of Core Technology Patent in Europe
2. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
3. Neuralstems ALS Trial on Clinical Hold
4. Neuralstems Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS
5. Neuralstem Receives FDA Approval to Commence Drug Trial for Major Depression
6. Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
7. Neuralstem Updates ALS Clinical Trial Progress
8. Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial
9. Neuralstem Updates NSI-189 Major Depression Trial
10. Neuralstem Announces Notice of Allowance for Two Additional Neurogenic Compound Patents
11. Dr. Eva Feldman, Principal Investigator, Presents Interim Data on Neuralstem ALS Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 1, 2014 Dyadic International, Inc. ("Dyadic") (OTCQX: ... technologies are used to develop, manufacture and sell enzymes ... and industrial enzyme industries, announced today that it will ... June 30, 2014 after market close on Thursday, August ... day at 5:00 p.m. Eastern Time to discuss those ...
(Date:7/31/2014)... 2014  According to data released today by the ... monthly Medicare Part D premium is expected to remain ... originally projected, the Pharmaceutical Care Management Association (PCMA) said. ... be a bright spot in American health care. By ... and using cutting edge, cost-saving tools like pharmacy networks ...
(Date:7/31/2014)... RMD ) today announced results for its fourth ... Revenue for the quarter was $415.2 million, flat compared to ... on a constant currency basis). Net income was $87.7 million, ... June 30, 2013. Diluted earnings per share for the quarter ... quarter ended June 30, 2013.  The results ...
Breaking Medicine Technology:Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13
... Reportlinker.com announces that a new market ... Triple Analysis: Lymphoma, Prostate ... http://www.reportlinker.com/p0284719/Triple-Analysis-Lymphoma-Prostate-Cancer-and-Antibodies.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology This triple analysis ... both Lymphoma and Prostate Cancer and by ...
... CYBX ), a global leader in epilepsy management, today ... Conference on Wednesday, June 8, 2011, in New York. ... Financial Officer, will speak to the attendees of the conference ... the presentation can be accessed by clicking on the Investor ...
Cached Medicine Technology:Reportlinker Adds Triple Analysis: Lymphoma, Prostate Cancer and Antibodies 2Reportlinker Adds Triple Analysis: Lymphoma, Prostate Cancer and Antibodies 3Reportlinker Adds Triple Analysis: Lymphoma, Prostate Cancer and Antibodies 4Reportlinker Adds Triple Analysis: Lymphoma, Prostate Cancer and Antibodies 5
(Date:8/1/2014)... at the University of California, San Diego School of ... in chili peppers produces chronic activation of a ... a reaction that ultimately reduces the risk of colorectal ... 1, 2014 issue of The Journal of Clinical ... TRPV1, was originally discovered in sensory neurons, where it ...
(Date:8/1/2014)... brain plays a central role in regulating appetite and ... in the brain,s control of food intake and body ... process has been unclear. A new study ... that PPARγ activity in a type of neuron known ... response to high-fat diet. Sabrina Diano and colleagues ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. 1, 2014 (HealthDay News) ... have significantly less endurance than those who weigh less, a new ... were obese, half were of normal weight -- people who were ... Obesity also was associated with less strength, increased discomfort and ... to 65 years of age -- neither improved nor reduced a ...
(Date:8/1/2014)... -- The U.S. Food and Drug Administration announced on ... help fight type 2 diabetes. Jardiance (empagliflozin) ... regimens to control blood sugar levels in the overall ... Office of Drug Evaluation II in the FDA,s Center ... statement. The FDA also recommended that Jardiance be ...
(Date:8/1/2014)... study, researchers at University Hospitals Rainbow Babies & Children,s ... at greater risk for death on a commercial airline ... worldwide between January 2010 and June 2013 and found ... age of 2. , The study was conducted ... of an in-flight pediatric fatality onboard commercial airline flights ...
Breaking Medicine News(10 mins):Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:New research characterizes in-flight pediatric deaths 2
... are smokers with implanted defibrillators had seven times higher a ... their heart into normal rhythm than nonsmokers with the device. ... School of Medicine in St. Louis .Eleven percent of cardiovascular ... that decreasing or quitting smoking is in itself a very ...
... A news study appearing in the June 15, 2006 ... Cancer Society, says that external beam radiation// could be ... years diagnosed with prostate cancer. ,Age has ... prostate cancer. In younger individuals, doctors recommend more aggressive ...
... was found that de- addiction drug help to combat alcoholism. ... Naltrexone//. This drug blocks craving for any sort of drug. ... American Medical Association. This drug can be made accessible ... of alcohol addicts. The two drugs that were tested are ...
... been warned against running long distances, as his health seems ... examined him//. ,The kid's clinical parameters such as ... are higher, according to Sugat Kar, Chief medical officer, Capital ... to have high blood pressure (135/85 mm Hg) and a ...
... the Human Fertility and Embryology Authority (HFEA) is evident that there ... a later age. Based on statistics it was seen that in ... or over. But in 2002, 24 babies were born to women ... NHS say that IVF should not be done to women over ...
... (IPF) is a disease whose cause and cure are not ... till date//. It is a lung disease characterized by scarring ... entire organ (lung). Statistics show that approximately 83,000 ... diagnosed every year. Ten years ago Jean Thompson became ...
Cached Medicine News:Health News:Jolt to Quit Smoking 2Health News:Slow Down Budhia, Warn Medical Experts 2Health News:Lesser Know Facts about Idiopathic Pulmonary Fibrosis (IPF) 2
Stainless steel bone clamp....
Designed for proximal femoral elevation in total hip replacement or in other surgery with a similar need for bone manipulation....
To elevate, dissect, scrape and apply traction to bone and soft tissue....
The AV Plus DX pacing lead is designed for use with the St. Jude Medical Affinity VDR pulse generator. This single-lead pacing system provides reliable pacing therapy with the added benefits of AV sy...
Medicine Products: